Erythropoietin Market to Soar from $17.29B in 2023 to $30.92B by 2028 at 12.6% CAGR, Driven by Rising CKD Incidence

The new report published by The Business Research Company, titled "Erythropoietin (EPO) Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the erythropoietin (epo) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $19.25 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3436&type=smp

Erythropoietin Market Gains Momentum Amid Rising Incidence Of Chronic Kidney Diseases
The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the coming years. The growing cases of chronic kidney disease require erythropoietin administration, which is used to make red blood cells to improve immunity. For instance, in March 2021, according to the Centers for Disease Control and Prevention's report published on chronic kidney disease in the United States, 15% of the adults in the USA, or 37 million people, were estimated to have chronic kidney disease (CKD). People aged 65 or older are more likely to have CKD (38%), followed by those aged 45-64 (13%), and those aged 18-44 (7%).Chronic kidney diseases lead to an anaemic condition, which in turn increases the demand for erythropoietin to curb the condition, thereby driving the market revenues.

Elanco's Varenzin-Ca1 Revolutionizes Anemia Treatment For Cats With Chronic Kidney Disease
Major companies operating in the erythropoietin market are developing innovative products such as Varenzin-CA1 to mark their position in the market. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats. For instance, in May 2023, Elanco, a US-based pharmaceutical company received FDA approval for Varenzin-CA1. It is developed exclusively for cats and features a mode of action that induces the genetic transcription of erythropoietin (EPO), increasing both EPO and red blood cell production in a cat's body. Varenzin-CA1 is a breakthrough innovation that meets at-home convenience and sets a new standard of care for cats suffering from nonregenerative anemia due to CKD.

The erythropoietin (epo) market covered in this report is segmented -
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Drug Class: Biologis, Biosimilar
3) By Application: Cancer, Hematology, Renal diseases, Neurology, Other Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=3436&type=discount

Major companies operating in the erythropoietin (epo) market report are BASF SE, Hoffmann-La Roche AG, Merck Sharp & Dohme LLC, Sanofi SA, Thermo Fisher Scientific Inc., Associated British Foods plc, DuPont de Nemours Inc., Kerry Group plc, Firmenich SA, Koninklijke DSM NV, Dyadic International Inc., Novozymes A/S, Endo International plc, Chr Hansen Holding A/S, Advanced Enzyme Technologies Ltd., Catalyst Pharmaceuticals Inc., Codexis Inc., AB Enzymes GmbH, Brain Biotech AG, Biocatalysts Ltd., Xike Biotechnology Co. Ltd., Amano Enzyme Inc., Enzyme Development Corporation, Lumis Biotech Pvt. Ltd., Teknisk-Kemiske Laboratorium ApS, Creative Enzymes Co. Ltd., BioResource International Inc., Enzyme Bioscience Pvt. Ltd., Sunson Industry Group Co. Ltd.

Contents of the report:
1. Executive Summary
2. Erythropoietin (EPO) Market Report Structure
3. Erythropoietin (EPO) Market Trends And Strategies
4. Erythropoietin (EPO) Market - Macro Economic Scenario
5. Erythropoietin (EPO) Market Size And Growth
…..
27. Erythropoietin (EPO) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/erythropoietins-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.